PL3658194T3 - Radioznacznik i środki radioterapeutyczne o podwójnym trybie działania - Google Patents

Radioznacznik i środki radioterapeutyczne o podwójnym trybie działania

Info

Publication number
PL3658194T3
PL3658194T3 PL18743540.9T PL18743540T PL3658194T3 PL 3658194 T3 PL3658194 T3 PL 3658194T3 PL 18743540 T PL18743540 T PL 18743540T PL 3658194 T3 PL3658194 T3 PL 3658194T3
Authority
PL
Poland
Prior art keywords
radiotracer
therapeutics
dual mode
dual
mode
Prior art date
Application number
PL18743540.9T
Other languages
English (en)
Polish (pl)
Inventor
Alexander Josef WURZER
Hans-Jürgen Wester
Matthias Johannes EIBER
Original Assignee
Technische Universität München
Technische Universität München - Klinikum Rechts Der Isar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technische Universität München, Technische Universität München - Klinikum Rechts Der Isar filed Critical Technische Universität München
Publication of PL3658194T3 publication Critical patent/PL3658194T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Nuclear Medicine (AREA)
PL18743540.9T 2017-07-28 2018-07-30 Radioznacznik i środki radioterapeutyczne o podwójnym trybie działania PL3658194T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17183795 2017-07-28
PCT/EP2018/070533 WO2019020831A1 (en) 2017-07-28 2018-07-30 AGENTS WITH TWO RADIOTRATIVE AND THERAPEUTIC MODES

Publications (1)

Publication Number Publication Date
PL3658194T3 true PL3658194T3 (pl) 2025-09-15

Family

ID=59501286

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18743540.9T PL3658194T3 (pl) 2017-07-28 2018-07-30 Radioznacznik i środki radioterapeutyczne o podwójnym trybie działania

Country Status (20)

Country Link
US (4) US11413360B2 (enExample)
EP (3) EP4424378A3 (enExample)
JP (2) JP7059372B2 (enExample)
KR (2) KR20240027896A (enExample)
CN (1) CN111132700B (enExample)
AU (2) AU2018308699B2 (enExample)
BR (1) BR112020001785A2 (enExample)
CA (1) CA3071315A1 (enExample)
DK (1) DK3658194T3 (enExample)
EA (1) EA202090370A1 (enExample)
ES (1) ES3011272T3 (enExample)
FI (1) FI3658194T3 (enExample)
HU (1) HUE070098T2 (enExample)
IL (2) IL272291B2 (enExample)
MX (2) MX2020000352A (enExample)
PL (1) PL3658194T3 (enExample)
PT (1) PT3658194T (enExample)
SG (1) SG11202000725WA (enExample)
WO (1) WO2019020831A1 (enExample)
ZA (1) ZA202000467B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240027896A (ko) 2017-07-28 2024-03-04 테크니쉐 우니베르지테트 뮌헨 이중 모드 방사성 트레이서 및 치료법
BR112021012110A2 (pt) * 2019-01-30 2021-09-08 Technische Universität München Radiofarmacêuticos substituídos por aceptor de fluoreto de silício
WO2020157177A1 (en) * 2019-01-30 2020-08-06 Technische Universität München Psma binding dual mode radiotracer and therapeutic
CA3128406A1 (en) * 2019-01-30 2020-08-06 Technische Universitat Munchen Cancer diagnostic imaging agents
CN112168978B (zh) * 2019-07-03 2022-01-11 北京大学 一种抗体偶联药物及其药物组合物与应用
EP4041213A4 (en) * 2019-10-29 2023-12-27 The Cleveland Clinic Foundation Psma-targeting imaging agents
CN113350531A (zh) * 2020-03-02 2021-09-07 上海核力星医药科技有限公司 前列腺特异性膜抗原结合配体偶联物及其应用
GB202005282D0 (en) * 2020-04-09 2020-05-27 Blue Earth Diagnostics Ltd Pharmaceutical Formulations
EP4185336A1 (en) 2020-07-23 2023-05-31 Technische Universität München Silicon-containing ligand compounds
KR20230066382A (ko) 2020-09-03 2023-05-15 큐리엄 유에스 엘엘씨 64Cu-DOTATATE의 스케일 업을 위한 방사성표지 및 제형
EP4023250A1 (en) * 2021-01-04 2022-07-06 Technische Universität München Dual mode radiotracer and -therapeutics
IL305134A (en) * 2021-02-15 2023-10-01 Technische Universit?T M?Nchen Dual mode radio and medical tracker
CA3215723A1 (en) * 2021-04-02 2022-10-06 Advanced Accelerator Applications Diagnostic methods of prostate cancer
JP2024517971A (ja) * 2021-05-14 2024-04-23 テクニシェ ユニバーシタット ミュンヘン 放射性医薬品のソマトスタチン受容体リガンドおよびその前駆体
GB202108779D0 (en) 2021-06-18 2021-08-04 Blue Earth Diagnostics Ltd Si-at therapeutic/diagnostic compounds
GB202109922D0 (en) 2021-07-09 2021-08-25 Blue Earth Diagnostics Ltd Radiotracers and therapeutics binding to fibroblast activation protein (fap)
US20250313579A1 (en) * 2021-08-05 2025-10-09 Technische Universität München Ligand compounds comprising a chelating group as a bridging group
GB202113646D0 (en) 2021-09-24 2021-11-10 Blue Earth Diagnostics Ltd Method of preparation of 18F labelled silyl-fluoride compounds
CN114671806B (zh) * 2022-04-08 2024-03-01 上海如絮生物科技有限公司 一种亲水性吡啶衍生物、中间体、其制备方法及应用
GB202207372D0 (en) 2022-05-19 2022-07-06 Blue Earth Diagnostics Ltd Synthesis of fluorosilyl compounds
JP2025525111A (ja) 2022-07-29 2025-08-01 テクニシェ ユニバーシタット ミュンヘン 放射性医薬品のためのケイ素系フッ化物アクセプター基
WO2024054226A1 (en) * 2022-09-06 2024-03-14 Hoang Ba Xuan Gallium nitrate and dimethyl sulfoxide composition for respiratory treatment
CA3264385A1 (en) * 2022-09-20 2024-03-28 Universität Augsburg NEW MINIGASTRINE-DERIVED CHOLECYSTOKIN 2 RECEPTOR-BINDING MOLECULES FOR TARGETED IMAGING AND RADIOTHERAPY
TW202426433A (zh) 2022-09-23 2024-07-01 瑞士商紐利迪姆股份公司 成纖維細胞活化蛋白(fap)抑制劑、fap結合物及其診斷與治療用途
IL319722A (en) 2022-09-23 2025-05-01 Nuclidium Ag High purity radionuclides and their diagnostic and medical uses
CN120417945A (zh) * 2022-11-14 2025-08-01 阿克提斯肿瘤学公司 肾脏中小蛋白滞留的减少
KR20260085122A (ko) 2023-09-29 2026-06-08 악티스 온콜로지, 인크. 미니단백질, 접합체 및 이의 용도
GB202316239D0 (en) 2023-10-24 2023-12-06 Blue Earth Diagnostics Ltd Therapeutic combination
WO2025250644A1 (en) * 2024-05-28 2025-12-04 Case Western Reserve University Fluorescent nuclide-containing agents for detecting and treating cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7384394A (en) * 1993-06-30 1995-01-24 Akzo Nobel N.V. Chelating compounds
EP1420831A1 (en) * 2001-07-27 2004-05-26 Targesome, Inc. Lipid constructs as therapeutic and imaging agents
CN102626522B (zh) * 2012-04-12 2014-09-10 韩彦江 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物
CA2949936C (en) * 2014-06-10 2022-10-18 3B Pharmaceuticals Gmbh Conjugate comprising a neurotensin receptor ligand and use thereof
EP3209336B1 (en) 2014-10-20 2019-12-11 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US20160287730A1 (en) * 2015-03-31 2016-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Labeled evans blue dye derivative for in vivo serum albumin labeling
EP3303349B1 (en) * 2015-05-26 2022-07-06 The Regents of the University of California Novel heteroaromatic silicon-fluoride-acceptors useful for 18f labeling of molecules and biomolecules, and methods of preparing same
KR20240027896A (ko) 2017-07-28 2024-03-04 테크니쉐 우니베르지테트 뮌헨 이중 모드 방사성 트레이서 및 치료법
DK3723815T3 (da) * 2017-12-11 2022-07-11 Univ Muenchen Tech PSMA ligander til billeddannelse og endoradioterapi
CA3128406A1 (en) 2019-01-30 2020-08-06 Technische Universitat Munchen Cancer diagnostic imaging agents
WO2020157177A1 (en) 2019-01-30 2020-08-06 Technische Universität München Psma binding dual mode radiotracer and therapeutic

Also Published As

Publication number Publication date
MX2020000352A (es) 2020-08-17
US20260021211A1 (en) 2026-01-22
EA202090370A1 (ru) 2020-05-25
KR20200064057A (ko) 2020-06-05
EP4424378A3 (en) 2024-12-11
US12453787B2 (en) 2025-10-28
ES3011272T3 (en) 2025-04-07
FI3658194T3 (fi) 2025-02-28
KR20240027896A (ko) 2024-03-04
JP2020528461A (ja) 2020-09-24
IL272291B1 (en) 2025-02-01
WO2019020831A1 (en) 2019-01-31
AU2018308699A1 (en) 2020-01-23
AU2024200440A1 (en) 2024-02-08
SG11202000725WA (en) 2020-02-27
US20220370649A1 (en) 2022-11-24
JP2022101601A (ja) 2022-07-06
EP3658194B1 (en) 2024-11-27
PT3658194T (pt) 2025-02-13
US12390540B2 (en) 2025-08-19
IL272291B2 (en) 2025-06-01
EP3658194A1 (en) 2020-06-03
CA3071315A1 (en) 2019-01-31
KR102752620B1 (ko) 2025-01-10
NZ760537A (en) 2026-01-30
IL318092A (en) 2025-02-01
AU2024200440B2 (en) 2025-04-24
MX2023007914A (es) 2023-07-13
CN111132700B (zh) 2022-12-13
US20200197545A1 (en) 2020-06-25
DK3658194T3 (da) 2025-02-17
US20250121102A1 (en) 2025-04-17
EP4424378A2 (en) 2024-09-04
HUE070098T2 (hu) 2025-05-28
EP4000640A1 (en) 2022-05-25
ZA202000467B (en) 2022-06-29
AU2018308699B2 (en) 2023-11-30
CN111132700A (zh) 2020-05-08
US11413360B2 (en) 2022-08-16
BR112020001785A2 (pt) 2020-09-29
IL272291A (en) 2020-03-31
JP7059372B2 (ja) 2022-04-25

Similar Documents

Publication Publication Date Title
ZA202000467B (en) Dual mode radiotracer and -therapeutics
GB201708456D0 (en) Senolytic compounds
GB201700814D0 (en) Compounds
GB201704327D0 (en) Compounds
GB201715342D0 (en) Compounds
GB201704325D0 (en) Compounds
HUE057745T2 (hu) Fenil-2-hidroxi-acetilamino-2-metil-fenil vegyületek
GB201815211D0 (en) Not known
GB201716871D0 (en) Compounds
GB201713962D0 (en) Compounds
GB201707938D0 (en) Compounds
GB201707856D0 (en) Compounds
GB201702221D0 (en) Compounds
GB201706162D0 (en) Compounds
GB201716369D0 (en) Compounds
GB201715786D0 (en) Compounds
GB201716392D0 (en) Compounds
GB201707852D0 (en) Compounds
GB201703282D0 (en) Compounds
GB201717050D0 (en) Compounds
GB201716688D0 (en) Compounds
GB201716374D0 (en) Compounds
GB201716352D0 (en) Compounds
GB201719821D0 (en) Karpopan
GB201713318D0 (en) Compounds